Ronald J. Stoney, MD, Co-Founder
Ronald J. Stoney, MD is emeritus professor of surgery at UCSF. In 1982, he co-founded the Pacific Vascular Research Foundation, now Vascular Cures, to improve patient care and prevent death and disability from vascular disease. That same year, he and an engineer colleague began the development of a self-retaining surgical retractor, the Omni-Tract that is now being used in surgical operations around the world. He served as President of the International Society for Cardiovascular Surgery, North American Chapter, and the Western Vascular Society. Dr. Stoney has received numerous awards, including the Society for Vascular Surgery’s Lifetime Achievement Award in 2007, and Honorary Doctor of Science degrees from the University of Ferrara, Italy in 1996 and from Santa Clara University, CA in 2008. He has lectured around the world, has published more than 100 book chapters and over 150 peer-reviewed articles, and authored and co-authored nine books on vascular surgery: two manuals, six atlases, and another on vascular exposures.
Lilia M. Coburn
Lilia M. Coburn brings 20 years of development of consumer engagement and behavior change products and is the founder of Heart, a high-tech product and marketing consultancy. Lilia is currently the Chief Product Officer at Fuzzy Pet Health. Most recently, she was Director of Product at 23andMe, Inc., where she was responsible for digital consumer engagement. Prior to 23andMe, she was President of MedHelp (a Merck subsidiary), an online and mobile health community with over 100 million annual users, where she drove the vision to bring forth a condition management platform combining behavioral science, user-centric design, and health data to affect healthy habits in patients. She has led product and engineering teams in the development and commercialization of consumer products in Silicon Valley, ranging from early-stage startups to top Fortune 500 companies. Her personal mission is to combine her high-tech background, her expertise in user experience and consumer engagement, and her passion for health and behavioral design, to spur innovative and effective preventive healthcare solutions. She holds a B.S. in Electrical Engineering from the University of Miami, and an MBA from the UC Berkeley Haas School of Business.
Michael S. Conte, MD, Chief Medical Officer
Michael S. Conte, MD is the Chief Medical Officer of Vascular Cures, Professor and Chief of the Division of Vascular and Endovascular Surgery at UCSF and Co-Director of the UCSF Heart and Vascular Center. Previously, he was the Associate Professor of Surgery at Harvard Medical School and Director of Vascular Surgery Research at Brigham and Women’s Hospital, Boston. He was also Co-Director of the Clinical Trials Group at the Center for Surgery and Public Health, a joint initiative of Harvard Medical School, Brigham and Women’s Hospital, and the Harvard School of Public Health. He has authored or co-authored more than 100 peer-reviewed publications, as well as numerous book chapters and reviews. He is a Distinguished Fellow of the Society for Vascular Surgery and has served on the scientific advisory board of several biotechnology/pharmaceutical companies. He served as an Associate Editor for Circulation, and is currently on the editorial boards of the Journal of Vascular Surgery, Vascular Medicine, Vascular and Endovascular Surgery, and Vascular.
Douglas P. Grey, MD
Douglas P. Grey, MD is a retired thoracic and vascular surgeon who practiced with The Permanente Medical Group (TPMG) for 28 years. He was the Chief of Vascular and Thoracic Surgery at Kaiser San Francisco, Chief of Surgery, and had various leadership roles within Northern California for TPMG. He was a founding member of the Kaiser Permanente National Procurement Organization and Product Council in 1994 and was the Northern California Representative to the National Product Council and the Chairman of the Biomedical Device Integration Council. In 1992, he co-founded Operation Access, an organization providing free medical procedures to uninsured populations. He received awards from both the American College of Surgeons (Pfizer Surgical Volunteerism) in 2009 and the American College of Clinical Engineering Health Technology Management (HTM) Champion Award in 2013. He is on the Board of Trustees of MedShare International, an NGO providing medical supplies and equipment to underserved communities and foreign hospitals.
Kevin Heath is the Medical Director leading the Education Solutions team within OptumCare Clinical Performance. Prior to his current role Dr. Heath led Clinical Chart Review Team within Clinical Performance and worked as a Management Services Organization Market Medical Director in Kansas City, KS/MO. Under Dr. Heath’s leadership, the Education Solutions team is implementing an Integrated Learning Series focused on diagnostic and documentation accuracy of the most common complex medical conditions within the senior population. Dr. Heath also serves as chair of the Clinical Performance Education Governing Board and is a member of the Atlas Governance Committee. He is a subject matter expert in the development and implementation of smart logic and suspect rules engines for Care Services. Dr. Heath is the Clinical Performance lead for the 2019 CLC initiative on screening strategies (including vascular outcomes), and he also participated in writing the clinical update for the 2020 Focus on Care. He is also partnering with the Harvard University/Brigham and Women’s Hospital Center for Cardiovascular Disease Prevention in the design and implementation of a large prospective vascular screening study.
Dr. Heath is board certified in nephrology and internal medicine and worked in a private nephrology practice in Dallas/Ft. Worth, Texas and as a hospitalist in Lawrence, Kansas. Dr. Heath received his undergraduate (BS, biology, and philosophy), graduate (MS, Clinical Anatomy), and doctorate (MD) degrees from Creighton University in Omaha, Nebraska. He completed an internal medicine residency at Creighton University Medical Center followed by a nephrology fellowship at Stanford University Hospital. Dr. Heath also holds a Master of Healthcare Leadership degree from Brown University and is a current Master of Public Health student in the epidemiology division of Harvard University’s T.H. Chan School of Public Health.
Wendy R. Hitchcock was CEO of Vascular Cures from 2009 to early 2019, and has over two decades of executive leadership in life science research and healthcare organizations. Prior to becoming CEO of Vascular Cures, she held CXO roles in both private and public biotech and medical device companies developing innovative products to address critical medical needs. These included Mercator MedSystems, a medical device company focused on treatments for peripheral artery disease (PAD) and critical limb-threatening ischemia (CLTI). Wendy has built significant enterprise value through collaborative partnering, strategic alliances, financing, and mergers and acquisitions. She is on the Patients Count Leadership Council of FasterCures and the Peripheral Vascular Disease Council of the American Heart Association. Wendy knows firsthand the importance of research to treat vascular disease. She was born with an arteriovenous malformation in her brain, which was successfully treated with surgery as an adult. She received her MBA from UCLA and BA from Brown University.
Bob Kain has over 3 decades of experience in the genomics and health space. He co-founded LunaPBC in 2017, a genomic/health database company, Revere BioSensors in 2015, focused on pathogen detection and worked at Illumina for 15 years. At Illumina, Bob led the invention of the modern, high throughput genome sequencer that brought the cost of sequencing a genome down from a half-million dollars to $1000 in 6 years. He joined Illumina pre-IPO in 1999 and retired in 2014, as the Chief Engineering Officer. Bob is the lead inventor on multiple U.S. patents and has spent much of his career at start-ups scaling people, processes, and systems as they grew revenue and market share. Prior to joining Illumina, Bob was the Director of the Microarray Business Unit at Molecular Dynamics. He is also the co-founder and chairman of the board of Mesa Rim Climbing Center, with multiple locations in San Diego, CA and Reno, Nevada. Bob received a BS in Physics from San Diego State University and an MBA from Saint Mary’s College of California.
Julie Lawrence is Program Officer with the Gordon and Betty Moore Foundation’s Patient Care Program, where she focuses on health system redesign, opportunities for technology to augment clinical care, and high-leverage strategies to improve patient safety. Before joining the foundation, Julie spent eight years at Stanford Healthcare. As a Design Fellow at the Clinical Excellence Research Center (CERC) at the Stanford School of Medicine, she researched and published a new model of cancer care delivery that improves quality and patient experience while dramatically reducing unnecessary healthcare spending. As a Director in Stanford’s Cancer Center, Julie used Lean performance improvement and Design Thinking innovations to improve care for patients, and was recognized by the FDA for outstanding contribution in promoting patient safety with medical devices. Julie served as Stanford’s representative to the National Comprehensive Cancer Network’s (NCCN) Best Practice Committee and Board Member of the National CyberKnife Coalition (CKC) addressing issues of advocacy and reimbursement parity for emerging cancer treatments. Julie is a speaker, author and advisor for digital health companies. Earlier in her career, Julie held positions at the University of California, San Francisco as Director of Strategic Planning, and as Managing Director of the Angara Group consultancy. In the 1990s, she worked for the International Finance Corporation in the former Soviet Union, advising government officials and entrepreneurs on economic transition. Julie received a B.S. in Russian from Georgetown University, an M.A. in International Studies from the Lauder Institute at the University of Pennsylvania, and an M.B.A. from the Wharton School at the University of Pennsylvania.
Megan D. Patterson, Chief Executive Officer
Megan Patterson, Chief Executive Officer, has a diverse background in the life sciences which includes roles in regulatory, marketing, business development, and project management. She has been involved primarily in the translational and clinical development stages of biologic, drug, device and diagnostic products. Megan established the U.S. office for Clinical Network Services, an international CRO and consulting firm focused on late pre-clinical and clinical product development and played a key role in establishing Coté Orphan Consulting, a regulatory affairs firm for orphan products in Washington, DC. She has also been honored with several awards for her work with non-profits and served as an AmeriCorps*VISTA (Volunteer in Service to America) as a community engagement manager in Ferguson, Missouri. Megan has a BS in Chemistry and Biochemistry, Cell & Molecular Biology from Drake University and a Masters in Business Science Keck Graduate Institute of Applied Life Sciences.
David M. Rae
David Rae is an Audit Partner in KPMG’s San Francisco Life Sciences practice. He has 16 years of experience providing financial statement audits, and audits of internal control to clients in the Life Sciences industry. Prior to studying accounting and joining KPMG, David earned his degree in life sciences, studying Biology and Biochemistry. David has provided professional audit services to several large multinational groups. He currently serves as the lead audit partner on a publicly traded, fully-integrated global medical device company. In addition, he serves and has served a number of biopharmaceutical companies ranging from early stage entities to fully-integrated commercial companies with global operations. David has extensive experience with SEC filings, including follow-on offerings, debt offerings, and carve-out financial statements. David has overseen dozens of acquisitions ranging in size from $20 million to more than $5 billion, and he has led complex global audits for clients in a variety of industries. He also serves as the lead recruiting partner for California State University, East Bay and UC Davis and delivers technical and industry presentations to the Universities’ students and faculty.
Margaret Wong is the Director of Managed Markets Marketing at Gilead Sciences, Inc. She has passion and extensive experience in translating technology innovation into value propositions that drive market access, strategic pricing and brand planning. Her diverse healthcare industry experiences span across biotech, pharmaceutical and medical devices serving patients living with liver diseases, diabetes, cardiovascular, cancer, autoimmune and pain management challenges. Margaret holds a MBA from Carnegie Mellon University, Graduate Certification in Applied HEOR from Thomas Jefferson University, and a M.S. and B.S. in Mechanical Engineering from UC Berkeley.
Edward K. Yu, Chair
After 30 years in corporate life and management consulting across technology and health industries, Ed is currently focused on improving societal health through innovation. Ed currently serves as the Chairman of Vascular Cures which is innovating patient-centric research, catalyzing breakthrough collaborations and empowering people in their vascular health journey. Ed is a retired PwC management consulting partner focused on strategy and business design. He has helped clients ranging from Fortune 50 conglomerates to early-stage companies. His expertise spans vision through execution including innovation strategy, product development and operations across the high-tech, medical device, diagnostics, genomics, therapeutics, payer, and provider sectors. Ed’s experience with senior executive coaching and facilitating cross-functional teams has earned him recognition for thought leadership and superior team performance. He has co-chaired PwC’s 180 Health Forum which convenes the c-suite to explore the new health economy and has spoken at many industry conferences, including talks for the Knowledge at Wharton program.